Related Experiment Videos
Trial endpoints for drug approval in oncology: Chemoprevention
1Food and Drug Administration, Center for Drug Evaluation and Research, Division of Oncology Drug Products, Rockville, Maryland 20857, USA.
Abstract:
As with other drugs, new drug applications for marketing approval of chemopreventive drugs must include data from adequate and well-controlled clinical trials that demonstrate effectiveness and safety for the intended use. This article summarizes the regulatory requirements for traditional marketing approval, as well as for approval under the accelerated approval regulations. Unlike traditional approval, accelerated approval is based on a surrogate endpoint that is reasonably likely to predict clinical benefit. Discussions with the Food and Drug Administration (FDA) regarding the validity of trial endpoints that may serve as surrogates for clinical benefit for accelerated approval should take place as early as possible in drug development. Meetings with the FDA to discuss these issues may be requested throughout the clinical development of a new drug.
Insights
New chemopreventive drugs require robust clinical trial data for marketing approval. Accelerated approval uses surrogate endpoints, necessitating early discussions with the Food and Drug Administration (FDA).
Area of Science:
- Regulatory Science
- Clinical Trial Design
- Drug Development
Background:
- Marketing approval for chemopreventive drugs necessitates comprehensive clinical trial data demonstrating safety and efficacy.
- Two primary regulatory pathways exist: traditional marketing approval and accelerated approval.
Purpose of the Study:
- To summarize the regulatory requirements for both traditional and accelerated marketing approval of chemopreventive drugs.
- To highlight the critical role of surrogate endpoints in accelerated approval and the importance of early FDA engagement.
Main Methods:
- Review of regulatory guidelines for drug marketing approval.
- Analysis of the criteria for traditional versus accelerated approval pathways.
- Emphasis on the Food and Drug Administration's (FDA) role in validating surrogate endpoints.
Main Results:
- Traditional approval requires definitive evidence of clinical benefit.
- Accelerated approval relies on surrogate endpoints reasonably likely to predict clinical benefit.
- Early and ongoing communication with the FDA is crucial for discussing and validating trial endpoints.
Conclusions:
- Understanding regulatory pathways is essential for successful drug development.
- Strategic engagement with the FDA early in development can streamline the approval process for chemopreventive drugs.
- The use of surrogate endpoints in accelerated approval requires careful consideration and validation.